Innovations in proteomic profiling of cancers: Alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology
Innovations in proteomic profiling of cancers: Alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology
复制标题
DOI：
10.1016/j.jprot.2013.04.007
复制
发表时间：
2013-09-02
影响因子：
3.3
通讯作者：
Zhang, Yang
中科院分区：
文献类型：
--
作者：
Omenn, Gilbert S.;Menon, Rajasree;Zhang, Yang
选择性剪接允许单个基因产生多个RNA转录物，其可以翻译成功能多样的蛋白质同种型。目前关于剪接的知识主要来自RNA转录本，对蛋白质的表达水平、3D结构和功能差异知之甚少。剪接是分子生物进化中的一个重要现象。简单报道蛋白质或mRNA表达上调或下调的研究受到这些异构体混合物的影响的混淆。除了了解混合物的净生物学效应之外，我们还可以根据特定疾病状态下特定剪接变体或剪接变体组合的可观察差异表达来开发生物标志物测试。在这里，我们回顾了我们的工作，在癌症中的剪接变异蛋白的差异表达和整合蛋白质组学分析与基于结构的构象预测的这种异构体之间的差异的可行性。本文是特刊的一部分，题为：从基因组到蛋白质组：开放式创新。(C)2013爱思唯尔有限公司版权所有。
Alternative splicing allows a single gene to generate multiple RNA transcripts which can be translated into functionally diverse protein isoforms. Current knowledge of splicing is derived mainly from RNA transcripts, with very little known about the expression level, 3D structures, and functional differences of the proteins. Splicing is a remarkable phenomenon of molecular and biological evolution. Studies which simply report up-regulation or down-regulation of protein or mRNA expression are confounded by the effects of mixtures of these isoforrns. Besides understanding the net biological effects of the mixtures, we may be able to develop biomarker tests based on the observable differential expression of particular splice variants or combinations of splice variants in specific disease states. Here we review our work on differential expression of splice variant proteins in cancers and the feasibility of integrating proteomic analysis with structure-based conformational predictions of the differences between such isoforms. This article is part of a Special Issue entitled: From Genome to Proteome: Open Innovations. (C) 2013 Elsevier B.V. All rights reserved.